99mTc labeling of highly potent small peptides

Bioconjugate Chemistry

Volumn 8, Issue 5, 1997, Pages 621-636

  Liu, Shuang ^a   Edwards, D Scott ^a   Barrett, John A ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LABELINGS;

DIAGNOSTIC AGENT; PEPTIDE; TECHNETIUM;

ANIMAL; CHEMISTRY; HUMAN; ISOTOPE LABELING; METHODOLOGY; REVIEW;

ANIMALS; HUMANS; ISOTOPE LABELING; PEPTIDES; TECHNETIUM;

EID: 0030611088     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc970058b     Document Type: Review

References (211)

1. Thakur, M. L. (1995) Radiolabeled peptides: now and future. Nucl. Med. Commun. 6, 724-732.
2. Zoghbi, S. S., Thakur, M. L., and Gottschalk, A. (1981) Selective cell labeling: a potential radioactive agent for labeling of human neutrophils. J. Nucl. Med. 22, P32 (abstract).
3. Baidoo, K. E., Stathis, M., Scheffiel, U., Lever, S. Z., and Wagner, H. N., Jr. (1993) High affinity Tc-labeled chemotactic peptides. J. Nucl. Med. 34, 18P (abstract 62).
4. Babich, J. W., Solomon, H., Pike, M. C., Kroon, D., Graham, W., Abrams, M. J., Tompkins, R. G., Rubin, R. H., and Fischman, A. J. (1993) Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. J. Nucl. Med. 34, 1967-1974.
5. 99mTc-labeled hydrazino nicotinic acid derivatized chemotactic peptides. Nucl. Med. Biol. 22, 25-30.
6. Fischman, A. J., Babich, J. W., and Rubin, R. H. (1994) Infection imaging with technetium-99m-labeled chemotactic peptide analogs. Semin. Nucl. Med. 24, 154-168, and references cited therein.
7. Fischman, A. J., Babich, J. W., and Strauss, H. W. (1993) A ticket to ride: peptide radiopharmaceuticals. J. Nucl. Med. 34, 2253-2263.
8. Fischman, A. J., Rauh, D., Solomon, H., Babich, J. W., Tompkins, R. G., Kroon, D., Strauss, H. W., and Rubin, H. R. (1993) In vivo bioactivity and biodistribution of chemotactic peptide analogs in nonhuman primates. J. Nucl. Med. 34, 2130-2134.
9. 111In IgG. Nucl. Med. Biol. 22, 643-648.
10. Babich, J. W., Solomon, H., Pike, M. C., Kroon, D., Graham, W., Abrams, M. J., Tompkins, R. G., Rubin, R. H., Barrow, S. A., and Fischman, A. J. (1993) Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. J. Nucl. Med. 34, 1964-1974.
11. Babich, J. W., Graham, W., Barrow, S. A., Dragotakes, S. C., Tompkins, R. H., Rubin, R. H., and Fischman, A. J. (1993) Technetium-labeled chemotactic peptides: comparison with Indium-111-labeled white blood cells for localizing acute bacterial infection in the rabbit. J. Nucl. Med. 34, 2176-2181.
12. Moyer, B. R., Vallabhajosula, S., Lister-James, J., Bush, L. R., Cyr, J. E., Snow, D. A., Bastidas, D., Lipszyc, H., and Dean, R. T. (1996) Technetium-99m-white blood cell-specific imaging agent developed from platelet factor 4 to detect infection. J. Nucl. Med. 37, 673-679.
13. Goodbody, A. E., Ballinger, J., Tran, L. L., Sumner-Smith, M., Lau, F., Meghji, K., and Pollak, A. (1994) A new Tc-99m labeled peptide inflammation imaging agent. Eur. J. Nucl. Med. 21, 790 (abstract 262).
14. Cavelier, V., Goodbody, A. E., Tran, L. L., Bossuyt, A., and Thornback, J. (1996) Human dosimetry of Tc99m-RP128, a potential inflammation imaging agent. Eur. J. Nucl. Med. 23, 1131 (abstract OMo398).
15. Peers, S. H., Tran, L. L., Eriksson, S. J., Ballinger, J., and Goodbody, A. E. (1995) Imaging a model of colitis with RP128, a Tc-99m-chelated tuftsin Antagonist. J. Nucl. Med. 36, 114P (abstract 465).
16. Maina, T., Stolz, B., Albert, R., Bruns, C., Koch, P., and Mäcke, H. (1994) Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219-387) labeled with technetium-99m. Eur. J. Nucl. Med. 21, 437-444.
17. 1]-octreotide, a new octreotide derivative with high affinity for somatostatin receptors. Technetium and Rhenium in Chemistry and Nuclear Medicine 4 (M. Nicolini, G. Banoli, and U. Mazzi, Eds.) pp 395-400, SGEditorali, Padova.
18. 111In-DTPA-octreotide. Pept. Res. 9, 144-150.
19. Vallabhajosula, S., Moyer, B. R., Lister-James, J., McBride, W. J., Lipszyc, H., Lee, H., Bastidas, D., and Dean, R. T. (1996) Preclinical evaluation of technetium-99m-labeled somatostatin receptor binding peptides. J. Nucl. Med. 37, 1016-1022.
20. Pearson, D. A., Lister-James, J., McBride, W. J., Wilson, D. M., Martel, L. J., Civitello, E. R., Taylor, J. E., Moyer, B. R., and Dean, R. T. (1996) Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. J. Med. Chem. 39, 1361-1371.
21. Barrett, J. A., Heminway, S. J., Damphousse, D. J., Thomas, J. R., Looby, R. J., Edwards, D. S., Harris, T. D., Rajopadhye, M., Liu, S., and Carroll, T. R. (1994) Platelet GP IIb/IIIa antagonists in the canine arteriovenous shunt: potential thrombus imaging agents. J. Nucl. Med. 35, 52P (abstract 202).
22. Harris, T. D., Barrett, J. A., Bourque, J. P., Carroll, T. R., Damphousse, P. R., Edwards, D. S., Glowacka, D., Liu, S., Looby, R. J., Poirier, M. J., Rajopadhye, M., and Yu, K. (1994) Design and synthesis of radiolabeled GPIIb/IIIa receptor antagonists as potential thrombus imaging agents. J. Nucl. Med. 35, 245P (abstract 1005).
23. Barrett, J. A., Bresnick, M. R., Crocker, A. C., Damphousse, D. J., Hampson, J. R., Heminway, S. J., Mazaika, T. J., Kagan, M., Lazewatsky, J. L., Edwards, D. S., Liu, S., Harris, T. D., Rajopadhye, M., and Carroll, T. R. (1995) RP-431: a potential thrombus imaging agent. J. Nucl. Med. 36, 16P (abstract 55).
24. 99mTc using aminocarboxylates as coligands. Bioconjugate Chem. 7, 63-71.
25. 99mTc by the preformed chelate approach: effects of chelators on properties Of [99mTc]chelator-peptide conjugate. Bioconjugate Chem. 7, 196-202.
26. 99mTc]chelator-peptide conjugates. Bioconjugate Chem. 7, 203-208.
27. 99mTc. Bioconjugate Chem. 8, 146-154.
28. 99mTc. Bioconjuate Chem. 8, 155-160.
29. Barrett, J. A., Bresnick, M., Crocker, A. C., Damphousse, D. J., Heminway, S. J., Mazaika, T. J., Kagan, M., Lazewatsky J. L., Edwards, D. S., Liu, S., Harris, T. D., Rajpladhye, M., and Carroll, T. R. (1997) RP431: a technetium-99m-labeled platelet GP IIbIIIa receptor antagonist as a thrombus imaging agent. J. Nucl. Med. (in press).
30. Knight, L. C., Radcliffe, R., Maurer, A. H., Rodwell, J. D., and Alvarez, V. L. (1994) Thrombus imaging with technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets. J. Nucl. Med. 35, 2842-288.
31. Lister-James, J., Knight, L. C., Mauer, A. H., Bush, L. R., Moyer, B. R., and Dean, R. T. (1996) Thrombus imaging with technetium-99m-labeled, activated platelet receptor binding peptide. J. Nucl. Med. 37, 775-781.
32. Muto, P., Lastoria, S., Varrella, P., Vergara, E., Salvatore, M., Morgano, G., Lister-James, J., Bernardy, J. D., Dean, R. T., Wencker, D., and Boer, J. S. (1995) Detecting deep venous thrombosis with technetium-99m-labeled synthetic peptide P280. J. Nucl Med. 36, 1384-1391.
33. Pearson, D. A., Lister-James, J., McBride, W. J., Wilson, D. M., Martel, L. J., Civitello, E. R., and Dean, R. T. (1996) Thrombus imaging using technetium-99m labeled high potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies. J. Med. Chem. 39, 1372-1382.
34. Lister-James, J., Vallabhajosula, S., Moyer, B. R., Pearson, D. A., McBride, B. J., De Rosch, M. A., Bush, L. R., Machac, J., and Dean, R. T. (1997) Pre-clinical evaluation of technetium-99m platelet receptor-binding peptide. J. Nucl. Med. 38, 105-111.
35. Goldenberg, D. M. (1989) Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy. Semin. Nucl. Med. 19, 332-339.
36. Parker, D. (1990) Tumor targeting with radiolabeled macrocycle-antibody conjugates. Chem. Soc. Rev. 19, 271-291.
37. Keenan, A. M., Harbert, J. C., and Larson, S. M. (1985) Monoclonal antibodies in nuclear medicine. J. Nucl. Med. 26, 532-537.
38. Verbruggen, A. M. (1990) Radiopharmaceuticals: state of the art. Eur: J. Nucl. Med. 17, 346-364.
39. Buchsbaum, D. J., and Lawrance, T. S. (1991) Tumor therapy with radiolabeled monoclonal antibodies. Antibody, Immunoconjugates, Radiopharm. 4, 245-272.
40. Serafini, A. N. (1993) From monoclonal antibodies to peptides and molecular recognition units: an overview. J. Nucl. Med. 34, 533-536.
41. Huston, J. S., George, A. J. T., Adams, G. P., Stafford, W. F., Jamar, F., Tai, M.-S., McCartney, J. E., Oppermann, H., Heelan, B. T., Peters, A. M., Houston, L. L., Bookman, M. A., Wolf, E. J., and Weiner, L. M. (1996) Single-chain Fv radioimmunotargeting. Q. J. Nucl. Med. 40, 320-333.
42. Delaloye, A. B., and Delaloye, B. (1995) Radiolabeled monoclonal antibodies in tumor imaging and therapy: out of fashion? Eur. J. Nucl. Med. 22, 571-580.
43. Behr, T. M., and Goldenberg, D. M. (1996) Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides. J. Nucl. Med. 37, 834-836 (Editorial).
44. 99mTc. Q. J. Nucl. Med. 40, 221-233.
45. McAfee, J. G., and Neumann, R. D. (1996) Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. Nucl. Med. Biol. 23, 673-676.
46. 99Tc]pertechnetate in aqueous solution. J. Nucl. Med. 21, 279-281.
47. 2 core. Inorg. Chem. 20, 1629-1632.
48. Abrams, M. J., Davison, A., Jones, A. G., and Costello, C. E. (1983) Synthesis and characterization of new Tc(IV) cation: Tris(acetylacetonato)-technetium(IV) tetrafluoroborate. Inorg. Chim. Acta 77, L235-L236.
49. Edwards, D. S., Liu, S., Poirier, M. J., Zhang, Z., Webb, G. A., and Orvig, C. (1994) Characterization of tris(N-substituted-2-methyl-3-hydroxy-4-pyridinonato)technetium(IV) cations. Inorg. Chem. 33, 5607-5609.
50. Deutsch, E., Vanderheyden, J.-L., Gerundini, P., Libson, K., Hirth, W., Colombo, F., Savi, A., and Fazio, F. (1987) Development of nonreducible technetium-99m(III) cations as myocardial perfusion imaging agents: initial experience in humans. J. Nucl. Med. 28, 1870-1880.
51. +, X = Cl, Br (DMPE = 1,2-bis-(dimethylphosphino)ethane). Int. J. Appl. Radiat. Isot. 34, 1611-1618.
52. +/2+, where DMPE = 1,2-bis(dimethylphosphino(ethane). Inorg. Chem. 25, 3367-3371.
53. Abrams, M. J., Davison, A., Jones, A. G., Costello, C. E., and Pang, H. (1983) Synthesis and characterization of hexakis(alkyl isocyanide) and hexakis(aryl isocyanide) complexes of technetium (I). Inorg. Chem. 22, 2798-2800.
54. Rao, T. N., Adhikesavalu, D., Camerman, A., and Fritzberg, A. R. (1990) Technetium(V) and rhenium(V) complexes of 2,3-bis(mercaptoacetamido)-propanoate. Chelate ring stereochemistry and influence on chemical and biological properties. J. Am. Chem. Soc. 112, 5798-5804.
55. Eshima, D., Taylor, A., Jr., Fritzberg, A. R., Kasina, S., Hansen, L., and Sorenson, J. F. (1987) Animal evaluation of technetium-99m triamide mercaptide complexes as potential renal imaging agents. J. Nucl. Med. 28, 1180-1186.
56. Vanbilloen, H. P., De Roo, M. J., and Verbruggen, A. M. (1996) Complexes of technetium-99m with tetrapeptides containing one alanyl and three glycyl moieties. Eur. J. Nucl. Med. 23, 40-48.
57. Subhani, M., Cleynhens, B., Bormans, G., Hoogmartens, M., De Roo, M., and Verbruggen, A. M. (1989) Complexes of technetium-99m with mercaptoacetyltripeptides: labeling characteristics and biodistribution in mice. Technetium and Rhenium in Chemistry and Nuclear Medicine 3 (M. Nicolini, G. Banoli, and U. Mazzi, Eds.) pp 453-461, Cortina International, Verona.
58. 3. Technetium and Rhenium in Chemistry and Nuclear Medicine 3 (M. Nicolini, G. Banoli, and U. Mazzi, Eds.) pp 661-666, Cortina International, Verona.
59. 99mTc-mercaptoacetyltripeptides. J. Labelled Compounds Radiopharm. 33, 1065-1078.
60. 99mTc-labelled agents. Nucl. Med. Biol. 22, 325-338.
61. Edwards, D. S., Cheesman, E. H., Watson, M. W., Maheu, L. J., Nguyen, S. A., Dimitre, L., Nason, T., Watson, A. D., and Walovitch, R. (1990) Synthesis and characterization of technetium and rhenium complexes of N, N′-1,2-ethylenediylbis-L-cysteine. Neurolite® and its metabolites. Technetium and Rhenium in Chemistry and Nuclear Medicine 3 (M. Nicolini, G. Banoli, and U. Mazzi, Eds.) pp 431-444, Cortina International, Verona.
62. Oya, S., Kung, M.-P., Frederick, D., and Kung, H. F. (1995) New bisaminoethanethiol (BAT) ligands which form two interconvertable Tc-99m complexes. Nucl. Med. Biol. 22, 749-757.
63. 99mTc-bis(aminoethanethiol) complexes: stereoisomers and biodistribution. J. Med. Chem. 32, 433-437.
64. 99mTc-TMR for brain imaging. Nucl. Med. Biol. 16, 829-837.
65. vO (M = Tc, Re) Amine-thiol complexes containing a pendant phenylpiperidine group. Inorg. Chem. 32, 3114-3124.
66. Meegalla, S., Plüssl, K., Kung, M.-P., Chumpradit, S., Stevenson, D. A., Frederick, D., and Kung, H. F. (1996) Tc-99m-labeled tropanes as dopamine transporter imaging agents. Bioconjugate Chem. 7, 421-429.
67. O'Neil, J. P., Wilson, S. R., and Katzenellenbogen, J. A. (1994) Preparation and structural characterization of monoamine-monoamide bis(thiol) oxo complexes of technetium(V) and rhenium(V). Inorg. Chem. 33, 319-323.
68. Lever, S. Z., Baidoo, K. E., and Mahmood, A. (1990) Structure proof of syn/anti isomerism in N-alkylated diaminedithiol (DADT) complexes of technetium. Inorg. Chim. Acta 176, 183-184.
69. 2 ligands: Synthesis and crystal structures. J. Chem. Soc., Dalton Trans., 1485-1490.
70. Spyriounis, D. M., Pelecanou, M., Stassinopoulou, C. I., Raptopoulou, C. P., Terzis, A., and Chiotellis, E. (1995) Synthesis and characterization of oxotechnetium(V) complexes with aza-substituted 2,6-dimethyl-4-azaheptane-2,6-dithiol ligands and benzyl mercaptan as coligand. Inorg. Chem. 34, 1077-1082.
71. Mastrostamatis, S. G., Papadopoulos, M. S., Pirmettis, I. C., Paschali, E., Varvarigou, A. D., Stassinopoulou, C. I., Raptopoulou, C. P., Terzis, A., and Chiotellis, E. (1994) Tridentate ligands containing the SNS donor atom set as a novel backbone for the development of technetium brain-imaging agents. J. Med. Chem. 37, 1077-1082.
72. Pirmettis, I. C., Papadopoulos, M. S., Mastrostamatis, S. G., Raptopoulou, C. P., Terzis, A., and Chiotellis, E. (1996) Synthesis and characterization of oxotechnetium(V) mixed-ligand complexes containing a tridentate N-substituted bis-(2-mercaptoethyl)amine and a monodentate thiol. Inorg. Chem. 35, 1685-1691.
73. Papadopoulos, M. S., Pelecanou, M., Pirmettis, I. C., Spyriounis, D. M., Raptopoulou, C. P., Terzis, A., Stassinopoulou, C. I., and Chiotellis, E. (1996) A new donor system [(SNN)(S)] for the synthesis of oxotechnetium(V) mixed-ligand complexes. Inorg. Chem. 35, 4478-4483.
74. Klingensmith III, W. C., Fritzberg, A. R., Spitzer, V. M., Johnson, D. L., Kuni, C. C., Williamson, M. R., Washer, G., and Weil III, R. (1984) Clinical evaluation of Tc-99m N,N′-bis(mercaptoacetyl)-2,3-diaminopropanoate as a replacement for I-131 hippurate: concise communication. J. Nucl. Med. 25, 42-48.
75. 99mTc-ECD). J. Cerebral Blood Flow Metab. 14, S4-S11.
76. Harris, T. D., Edwards, D. S., and Platts, S. H. (1992) Synthesis and characteristics of isomers L,L, D,D, and D,L of Tc-99m-ECD in monkeys. J. Nucl. Med. 33, 979-980.
77. 1A receptor imaging agents. In Technetium and Rhenium in Chemistry and Nuclear Medicine 4 (M. Nicolini, G. Banoli, and U. Mazzi, Eds.) pp 293-298, SGEditorali, Padova.
78. 99mTc complex as a dopamine transporter imaging agent. J. Am. Chem. Soc. 117, 11037-11038.
79. Meegalla, S., Plössl, K., Kung, M-P., Chumpradt, S., Stevenson, D. A., Kushner, S. A., McElgin, W. T., Mozley, P. D., and Kung, H. F. (1997) Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agnets. J. Med. Chem. 40, 9-17.
80. 9). Inorg. Chem. 28, 3411-3416.
81. Linder, R. E., Malley, M. F., Gougoutas, J. Z., Unger, S. E., and Nunn, A. D. (1990) Neutral, seven-coordinated dioxime complexes of technetium(III): synthesis and characterization. Inorg. Chem. 29, 2428-2434.
82. 2(BDI)BEt (DMG = dimethylglyoxime, BDI = butane-2,3-dione imine-oxime). Inorg. Chim. Acta 190, 249-255.
83. 99mTc complexes. Nucl. Med. Biol. 23, 567-584.
84. 3 PITC. Bioconjugate Chem. 2, 160-170.
85. 2. Bioconjugate Chem. 2, 407-414.
86. Lanteingne, D., and Hnatowich, D. J. (1984) The labeling of DTPA coupled proteins. Int. J. Radiat. Isot. 35, 617-621.
87. 2. Inorg. Chem. 26, 3576-3582.
88. Ianoz, E., Mantegazzi, D., and Lerch, P. (1989) Preparation, crystal and molecular structure of trans-dioxo(1,4-dithia-8,11-diazacyclotetradecane)-technetium(V) hexafluorophosphate. Inorg. Chim. Acta 156, 235-239.
89. Kelly, J. D., Forster, A. M., Archer, C. M., Booker, F. S., Canning, L. R., Chiu, R. W., Edwards, B., Gill, H. R., McPartlin, M., Nagle, R. R., Latham, I. A., Pickett, R. D., Storey, A. E., and Webbon, P. M. (1993) Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J. Nucl. Med. 34, 222-227.
90. Higley, B., Smith, F. W., Gemmell, H. G., Gupta, P. D., Gvozdanovic, D. V., Graham, D., Hinge, D., Davidson, J., and Lahiri, A. (1993) Technetium-99m1,2-bis[bis(2-ethoxyethyl)-phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J. Nucl. Med. 34, 30-38.
91. Jones, S., and Hendel, R. C. (1993) Technetium-99m tetrofosmin: a new myocardial perfusion agent. J. Nucl. Med. Technol. 21, 191-195.
92. Schwochau, R. (1994) Technetium radiopharmaceuticals-fundamentals, synthesis, structure, and development. Angew. Chem., Int. Ed. Engl. 33, 2258-2267.
93. Abrams, M. J., Juweid, M., tenKate, C. I., Schwartz, D. A., Hauser, M. M., Gaul, F. E., Fuccello, A. J., Rubin, R. H., Strauss, H. W., and Fischman, A. J. (1990) Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J. Nucl. Med. 31, 2022-2028.
94. 99mTc-protein conjugates. Bioconjugate Chem. 2, 334-336.
95. 99mTc labeling of hydrazino nicotinamide modified human polyclonal IgG. J Nucl. Med. 35, 105P.
96. 99mTc]tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjugate Chem. 6, 635-638.
97. 99mTc. Nucl. Med. Biol. 16, 171-176.
98. Fritzberg, A. R., Berninger, R. W., Hadley, S. W., and Wester, D. W. (1988) Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer. Pharm. Res. 5, 325-334.
99. Otsuka, F. L., and Welch, M. J. (1987) Methods to label monoclonal antibodies for use in tumor imaging. Nucl. Med. Biol. 14, 243-249.
100. Hnatowich, D. J. (1990) Antibody radiolabeling, problems and promises. Nucl. Med. Biol. 17, 49-55.
101. Hnatowich, D. J. (1990) Recent developments in radiolabeling of antibodies with iodine, indium, and technetium. Semin. Nucl. Med. 20, 80-91.
102. Srivastava, S. C., and Mease, R. C. (1991) Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies. Nucl. Med. Biol. 18, 589-603.
103. Delmon-moingeon, L. I., Mahmood, A., Davison, A., and Jones, A. G. (1991) Strategies for labeling monoclonal antibodies and antibody-like molecules with technetium-99m. J. Nucl. Biol. Med. 35, 47-59.
104. 99mTc. Nucl. Med. Biol. 18, 667-676.
105. 99mTc. Nucl. Med. Biol. 18, 3-7.
106. Liu, Y.-F., and Wu, C.-C. (1991) Radiolabeling of monoclonal antibodies with metal chelates. Pure Appl. Chem. 63, 427-463.
107. Griffiths, G. L., Goldenberg, D. M., Jones, A. L., and Hansen, H. J. (1992) Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconjugate Chem. 3, 91-99.
108. Bhargava, K. K., and Acharya, S. A. (1989) Labeling of monoclonal antibodies with radionuclides. Semin. Nucl. Med. 19, 187-201.
109. Wolf, W., and Shani, J. (1986) Criteria for the selection of the most desirable radionuclide for radiolabeling monoclonal antibodies. Nucl. Med. Biol. 13, 319-324.
110. Gansow, O. A. (1991) Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. Nucl. Med. Biol. 18, 269-281.
111. Zamora, P. O., and Rhodes, B. A. (1992) Imidazoles as well as thiolates in proteins bind technetium-99m. Bioconjugate Chem. 3, 493-498.
112. Fritzberg, A. R., Abrams, P. G., Beaumier, P. L., Kasina, S., Morgan, A. C., Rao, T. N., Reno, J. M., Sanderson, J. A., Srinivasan, A., and Wilbur, D. S. (1988) Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc. Natl. Acad. Sci. U.S.A. 85, 4025-4029.
113. Eary, J. F., Schroff, R. W., Abrams, P. G., Fritzberg, A. R., Morgan, A. C., Kasina, S., Reno, J. M., Srinivasan, A., Woodhouse, C. S., Wilbur, D. S., Natale, R. B., Collins, C., Stehlin, J. S., Mitchell, M., and Nelp, W. B. (1989) Successful imaging of malignant melanoma with technetium-99m-labeled monoclonal antibodies. J. Nucl. Med. 30, 25-32.
114. Kasina, S., Rao, T. N., Srinivasan, A., Sanderson, J. A., Fitzner, J. N., Reno, J. M., Beaumier, P. L., and Fritzberg, A. R. (1991) Development and biological evaluation of a kit for preformed chelate technetium-99m radiolabeling of an antibody Fab fragment using a diamide dimercaptide chelating agent. J. Nucl. Med. 32, 1445-1451.
115. Majocha, R. E., Reno, J. M., Friedland, R. P., VanHaight, C., Lyle, L. R., and Marotta, C. A. (1992) Development of a monoclonal antibody specific for β/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy. J. Nucl. Med. 33, 2184-2189.
116. 3S triamidethiols as bifunctional chelating agents for labeling small peptides with technetium-99m. In Technetium and Rhenium in Chemistry and Nuclear Medicine 4 (M. Nicolini, G. Banoli, and U. Mazzi, Eds.) pp 383-393, SGE-ditorali, Padova.
117. Rajopadhye, M., Edwards, D. S., Bourque, J. P., and Carroll, T. R. (1996) Synthesis and technetium-99m labeling of cyclic GPIIb/IIIa receptor antagonists conjugated to 4,5-bis(mercaptoacetylamido)pentanoic acid (mapt). Bioorg. Med. Chem. Lett. 6, 1737-1740.
118. Baidoo, K. E., and Lever, S. Z. (1990) Synthesis of a diaminedithiol bifunctional chelating agent for incorporation of technetium-99m into biomolecules. Bioconjugate Chem. 1, 132-137.
119. Lever, S. Z., Baidoo, K. E., Mahmood, A., Matsumura, K., Scheffel, U., and Wagner, H. N., Jr. (1994) Novel technetium ligand with affinity for muscarinic cholinergic receptor. Nucl. Med. Biol. 21, 157-164.
120. Lever, S. Z., Sun, S-Y., Scheffel, U. A., Kaltovich, F. A., Baidoo, K. E., Goldfarb, H., and Wagner, H. N., Jr. (1994) Pulmonary accumulation of neutral diamine dithiol complexes of technetium-99m. J. Pharm. Sci. 84, 802-809.
121. 99m/99Tc-DADT-Benzovesamicol: a potential marker for cholinergic neurons. Nucl. Med. Biol. 21, 197-203.
122. O'Neil, J. P., Anderson, C. J., Carlson, K. E., Welch, M. J., and Katzenellenbogen, J. A. (1993) An improved progestintechnetium complex as a potential imaging agent for steroid receptors. J. Nucl. Med. 33, 18P (abstract 61).
123. 99mTc-labeling. J. Labelled Comp. Radiopharm. 29, 1283-1291.
124. Eisenhut, M., Lehmann, W. D., Becker, W., Elser, H., Strittmatter, W., Baum, R. P., Valerius, T., Repp, R., and Deo, Y. (1996) Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immunoreactivity and kit formulation. J. Nucl. Med. 37, 362-370.
125. DiZio, J. P., Fiashi, R., Davison, A., Jones, A. G., and Katzenellenbogen, J. A. (1991) Progestin-rhenium complexes: metal labeled steroids with high receptor binding affinity, potential receptor-directed agents for diagnostic imaging or therapy. Bioconjugate Chem. 2, 352-366.
126. 2-metal conjugate. Bioconjugate Chem. 5, 182-193.
127. DiZio, J. P., Anderson, C. J., Davison, A., Ehrhardt, G. J., Carlson, K. E., Welch, M. J., and Katzenellenbogen, J. A. (1992) Technetium- and rhenium-labeled progestins: synthesis, receptor binding and in vivo distribution of an β-substituted progestin labeled with technetium-99m and rhenium-186. J. Nucl. Med. 33, 558-569.
128. 99mTc-labeling kinetics of four thiol-containing chelators and 2-hydrazinopyridine: factors influencing their radiolabeling efficiency. Appl. Radiat. Isot. (in press).
129. Bryson, N., Lister-James, J., Jones, A. G., Davis, W. M., and Davison, A. (1990) Protecting groups in the preparation of thiolate complexes of technetium. Inorg. Chem. 29, 2948-2951.
130. Bryson, N., Dewan, J. C., Lister-James, J., Jones, A. G., and Davison, A. (1988) Neutral technetium(V) complexes with amide-thiol-thioether chelate ligands. Inorg. Chem. 27, 2154-2161.
131. Anderson, F. A., Wheeler, H. B., Goldberg, R. T., Hosner, D. W., Patwardhar, N. A., Jovanovic, B., Forcier, A., and Dalen, J. E. A. (1991) A population-based perspective of the hospital incidence and case facility rates of deep vein thrombosis and pulmonary embolism. Ann. Intern. Med. 151, 933-938.
132. Hull, R. D., Hirsh, J., Carter, D. J., Jay, R. M., Dodd, P. E., Ockelford, P. A., Coates, G., Gill, G. J., Turpie, A. G., Dayle, D. J., Buller, H. R., and Raskob, G. E. (1983) Pulmonary angiography, ventilation lung scanning and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann. Intern. Med. 98, 891-938.
133. Knight, L. C. (1990) Radiopharmaceuticals for thrombus detection. Semin. Nucl. Med. 20, 52-67.
134. Knight, L. C. (1993) Scintigraphic methods for detecting vascular thrombus. J. Nucl. Med. 34, 554-561.
135. Wasser, M. N. J. M., and Pauwels, E. K. J. (1990) Immunoscintigraphy of thrombosis. Eur. J. Nucl. Med. 16, 583-585 (Editorial).
136. Loscalzo, J., and Rocco, T. P. (1992) Imaging arterial thrombi: an elusive goal. Circulation 85, 382-384.
137. Som, P., and Oster, Z. H. (1994) Thrombus-specific imaging: approaching the elusive goal. J. Nucl. Med. 35, 202-203 (Editorial).
138. 125I-labelled fibrinogen. Br. J. Surg. 55, 742-747.
139. 125I-labelled fibrinogen in diagnosis of deep-vein thrombosis and its correlation with phlebography. Br. J. Surg. 55, 835-839.
140. Thakur, M. L., Welch, M. J., Joist, J. H., and Coleman, R. E. (1976) Indium-111-labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb. Res. 9, 345-357.
141. Ezekowitz, M. D., Leonard, J. C., Smith, E. O., Allen, E. W., and Taylor, F. B. (1981) Identification of left ventricular thrombi in man using indium-111-labeled autologous platelets. Circulation 63, 801-810.
142. Stratton, J. R., Ritchie, J. L., Hamilton, G. W., Hammermeister, K. E., and Harker, L. A. (1981) Left ventricular thrombi: in vivo detection by indium-111 platelet imaging and two dimentional echocardiography. Am. J. Cardiol. 47, 874-881.
143. Ezekowitz, M. D., Eichner, E. R., Scatterday, R., and Elkins, C. R. (1982) Diagnosis of a persistent pulmonary embolus by indium-111 platelet scintigraphy with angiography and tissue confirmation. Am. J. Med. 72, 839-842.
144. 111In-labeled autologous platelets in venous thromboembolism. Radiology 136, 203-207.
145. Fenech, A., Hussey, J. K., Smith, F. W., Dendy, P. P., Bennett, B., and Douglas, A. S. (1981) Diagnosis of deep vein thrombosis using autologous indium-111-labeled platelets. Br. Med. J. 282, 1020-1022.
146. Stratton, J. R. (1991) Thrombosis imaging with indium-111-labeled platelets. Cardiac Imaging - Principles and Practice (M. L. Marcus, H. R. Schelbert, D. J. Skorton, and D. J. Wolf, Eds.) pp 1121-1134, W. B. Saunders, New York.
147. Stratton, J. R., Cerqueira, M. D., Dewhurst, T. A., and Kohler, T. R. (1994) Imaging arterial thrombosis: comparison of technetium-99m-labeled monoclonal antifibrin antibodies and indium-111-platelets. J. Nucl. Med. 35, 1731-1737.
148. Ali, F. E., Bennett, D. B., Calvo, R. R., Elliott, J. D., Hwang, S. M., Ku, T. W., Lago, M. A., Nichols, A. J., Romoff, T. T., Shah, D. H., Vasko, J. A., Wong, A. S., Yellin, T. O., Yuan, C-K., and Samanen, J. M. (1994) Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation. J. Med. Chem. 37, 769-780, and references cited therein.
149. 3 antagonists. J. Med. Chem. 37, 1-8, and references cited therein.
150. Teng, W., Rose, J. W., Phillips, D. R., Nannizzi, L., Arsen, A., Campbell, A. M., and Charo, I. F. (1993) Design of potent and specific integrin antagonists. J. Biol. Chem. 268, 1066-1073.
151. Zablocki, J. A., Miyano, M., Garland, R. B., Pireh, D., Schretzman, L., Rao, S. N., Lindmark, R. J., Panzer-Knodle, S. G., Nicholson, N. S., Taite, B. B., Salyers, A. K., King, L. W., Campion, J. G., and Feigen, L. P. (1993) Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb/IIIa receptor. J. Med. Chem. 36, 1811-1919.
152. Bach, A. C., II, Eyermann, C. J., Gross, J. D., Bower, M. J., Harlow, R. L., Weber, P. C., and DeGrado, W. F. (1994) Structural studies of a family of high affinity ligands for GPIIb/IIIa. J. Am. Chem. Soc. 116, 3207-3219.
153. Jackson, S., DeGrado, W. F., Dwivedi, A., Parthasarathy, A., Higley, A., Krywko, J., Rockwell, A., Markwalder, J., Wells, G., Wexler, R., Mousa, S., and Harlow, R. L. (1994) Template-constrained cyclic peptides: design of high-affinity ligands for GPIIb/IIIa. J. Am. Chem. Soc. 116, 3220-3230.
154. α-methylarginine-containing peptide. J. Org. Chem. 60, 946-952.
155. Wityak, J., Fevig, J. M., Jackson, S. A., Johnson, A. L., Mousa, S. A., Parthasarthy, A., Wells, G. J., DeGrado, W. F., and Wexler, R. R. (1995) Synthesis and antiplatelet activity of DMP757 analogs. Bioorg. Med. Chem. Lett. 5, 2097-2100.
156. Harris, T. D., Rajopadhye, M., Damphousse, P. R., Glowacka, D., Yu, K., Bourque, J. P., Barrett, J. A., Damphousse, D. J., Heminway, S. J., Lazewatsky, J. L., Mazaika, T., and Carroll, T. R. (1996) Tc-99m-labeled fibrinogen receptor antagonists: design and synthesis of cyclic RGD peptides for the detection of thrombi. Bioorg. Med. Chem. Lett. 6, 1741-1746.
157. Rajopadhye, M., Harris, T. D., Yu, K., Glowacka, D., Damphousse, P. R., Barrett, J. A., Heminway, S. J., Edwards, D. S., and Carroll, T. R. (1997) Synthesis, evaluation and Tc-99m complexation of a hydrazinonicotinyl conjugate of a GP IIb/IIIa antagonist cyclic peptide for the detection of deep vein thrombosis. Bioorg. Med. Chem. Lett. 7, 955-960.
158. Liu, S., and Edwards, D. S. Unpublished results.
159. 2. Inorg. Chim. Acta 185, 7-15.
160. Archer, C. M., Dilworth, J. R., Jobanputra, P., Thompson, R. M., McPartlin, M., Povey, D. C., Smith, G. W., and Kelly, J. D. (1990) Development of new technetium cores containing technetium-nitrogen multiple bonds. Synthesis and characterization of some diazenido-, hydrazido- and imido-complexes of technetium. Polyhedron 9, 1497-1502.
161. 3)]. Z. Naturforsch. 46, 449-452.
162. 2O. J. Chem. Soc., Dalton Trans., 897-904.
163. 4]. J. Chem. Soc., Dalton Trans., 1251-1256.
164. 2]. In Technetium and Rhenium in Chemistry and Nuclear Medicine 3 (M. Nicolini, G. Bandoli, and U. Mazzi, Eds.) pp 95-108, Cortina International, Verona.
165. 2. In Technetium and Rhenium in Chemistry and Nuclear Medicine 3 (M. Nicolini, G. Bandoli, and U. Mazzi, Eds.) pp 65-68, Cortina International, Verona.
166. 4N)]. Inorg. Chim. Acta 252, 421-426.
167. 4N)]. Inorg. Chim. Acta 252, 427-430.
168. Oyen, W. J. G., Boerman, O. C., van der Laken, C. J., Claessens, R. A. M. J., van der Meer, J. W. M., and Corsten, F. H. M. (1996) The uptake mechanisms of inflammation- and infection-localizing agents. Eur. J. Nucl. Med. 23, 459-465.
169. Boxen, I., and Ballinger, J. R. (1991) Nuclear Medicine detection of inflammation and infection. Curr. Opin. Radiol. 3, 840-850.
170. McAfee, J. G. (1990) What is the best method for imaging focal infections? J. Nucl. Med. 31, 413-416 (Editorial).
171. Claessens, R. A. M. J., Koenders, E. B., Oyen, W. J. G., and Corstens, F. H. M. (1996) Retention of technetium-99m in infectious foci in rats after release from technetiun-99m labelled human non-specific polyclonal immunoglobulin G: a dual-label study with hydrazinonicotinamido and iminothiolano immunoglobulin. Eur. J. Nucl. Med. 23, 1536-1539.
172. 99mTc-human immunoglobulin (HIG)-first results of a new agent for the localization of infection and inflammation. Eur. J. Nucl. Med. 16, 649-655.
173. 3 and SHNH: an in vitro and animal in vivo comparison. Nucl. Med. Biol. 23, 917-922.
174. Barrow, S. A., Graham, W., Jyawook, S., Dragotakes, S. C., Solomon, H. F., Babich, J. W., Rubin, R. H., and Fischman, A. J. (1993) Localization of indium-111-immunoglobulin G, technetium-99m-immunoglobulin G and indium-111-labeled white blood cells at sites of acute bacterial infection in rabbits. J. Nucl. Med. 34, 1975-1979.
175. Callahan, R. J., Barrow, S. A., Abrams, M. J., Rubin, R. H., and Fischman, A. J. (1996) Biodistribution and dosimetry of technetium-99m-hydrazino nicotinamide IgG: comparison with indium-111-DTPA-IgG. J. Nucl. Med. 37, 843-846.
176. 99mTc-labeled human polyclonal IgG. Nucl. Med. Biol. 21, 111-116
177. 99mTc-hexamethylpropyleneamineoxime for labeling leukocytes and imaging inflammation. Lancet 2, 946-949.
178. Vorne, M., Soini, I., Lantto, T., and Paakkinen, S. (1989) Technetium-99m-HM-PAO-labeled leukocytes in detection of inflammatory lesions: comparison with gallium-67 citrate. J. Nucl. Med. 30, 1332-1336.
179. Charron, M., Orenstein, S. R., and Bhargava, S. (1994) Detection of inflammatory bowel disease in pediatric patients with technetium-99m-HMPAO-labeled leukocytes. J. Nucl. Med. 35, 451-455.
180. Peters, A. M. (1996) The choice of an appropriate agent for imaging inflammation. Nucl. Med. Commun. 17, 455-458.
181. Lange, J. M. A., Boucher, C. A. B., Hollak, C. E. M., Wiltink, E. H. H., Reiss, P., van Royen, E. A., Roos, M., Danner, S. D., and Goudsmit, J. (1990) Failure of zidovudine prophylaxis after accidental exposure to HFV-1. N. Engl. J. Med. 322, 1375-1377.
182. Rojas-Burke, J. (1990) Health officials reacting to infection mishaps. J. Nucl. Med. 33, 13-27.
183. Edwards, D. S., Barrett, J. A., Liu, S., Ziegler, M. C., Mazaika, T., Vining, M., Bridger, G., Higgins, III, J., and Abrams, M. J. (1996) A stabilized Tc-99m complex of a chemotactic peptide-HYNIC conjugate for imaging infection. Eur. J. Nucl. Med. 23, 1142 (abstract Omo440).
184. 99mTc-labelled chemotactic peptides: analogues with reduced neutropenia. Nucl. Med. Commun. 17, 132-139.
185. Solomon, H. F., Derlan, C. K., Beblavy, M., Jester, D., Santull, R., Pike, M., Kroon, D., Hoey, K., and Fischman, A. J. (1994) Focal infection imaging using an In-111 labeled antagonist chemotactic peptide. J. Nucl. Med. 35, 45P (abstract 172).
186. Reubi, J. C. (1993) The role of peptides and their receptors as tumor markers. Endocrinol. Metab. Clin. North Am. 22, 917-939.
187. Virgolini, I., Pangerl, T., Bischof, C., Leimer, M., Kartaran, A., Yang, Q., Peck-Radosavjlevic, M., Kaserer, K., Niederle, B., Angelberger, P., Gangl, A., and Valent, P. (1996) Somatostatin (SST) and vasoactive intestinal peptide (VIP) receptor® subtype expression. Eur. J. Nucl. Med. 23, 1101 (abstract Omo274).
188. 111In-DTPA-Phe-1-octreotide. Nucl. Med. Commun. 14, 550-558.
189. Reubi, J. C. (1995) Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J. Nucl. Med. 36, 1825-1835.
190. 131I-tyrosyl somatostatin. Br. J. Radiol. 49, 381-382.
191. Wangberg, B., Nilsson, O., Theodørsson, E., Dahlstrøm, A., and Ahlman, H. (1991) The effect of a somatostatin analog on the release of hormones from human midgut carcinoid tumor cells. Br. J. Cancer 64, 23-28.
192. Lamberts, S. W. J. (1988) The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogues in the treatment of human pituitary tumors. Endocrinol. Rev. 9, 417-436.
193. Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., and Pless, J. (1982) SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31, 1133-1140.
194. Weckbecker, G., Liu, R., Tolcsvai, L., and Bruns, C. (1992) Antiproliferative effects of octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res. 52, 4973-4978.
195. Bakker, W. H., Krenning, E. P., Breeman, W. A. P, Koper, J. W., Kooij, P. P. M., Reubi, J. C., Klijn, J. G., Visser, T. J., Docter, R., and Lamberts, S. W. J. (1990) Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity and in vivo application in animals. J. Nucl. Med. 31, 1501-1509.
196. Krenning, E. P., Breeman, W. A., Bakker, W. H., Koper, J. W., Kooij, P. P., Ansema, L., Lamberts, S. W. J., and Reubi, J. C. (1989) Localization of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet 1, 242-243.
197. 1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci. 49, 1593-1601.
198. Lipp, R. W., Silly, H., Ranner, G., Dobnig, H., Passath, A., Leb, G., and Krejs, G. J. (1995) Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J. Nucl. Med. 36, 13-18.
199. Moretti, J. L., Caglar, M., Boaziz, C., Caillat-Vigneron, N., and Morere, J. F. (1995) Sequential functional imaging with technetium-99m hexakis-2-methoxy-isobutylisonitrile and indium-111 octreotide: can we predict the response to chemotherapy in small cell lung cancer? Eur. J. Nucl. Med. 22, 177-180.
200. Tenebaum, F., Lumbroso, J., Schlumberger, M., Mure, A., Plouin, P. F., Cailou, B., and Parmentier, C. (1995) Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J. Nucl. Med. 36, 1-6.
201. Haldemann, A. R., Rösler, H., Barth, A., Waser, B., Geiger, L., Godoy, N., Markwalder, R. V., Seiler, R. W., Sutzer, M., and Reubi, J. C. (1995) Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability. J. Nucl. Med. 36, 403-410.
202. Maini, C. L., Cioffi, R. P., Tofani, A., Sciuto, R., Fontana, M., and Carapella, C. M. (1995) Indium-111 octreotide scintigraphy in neurofibromatosis. Eur. J. Nucl. Med. 22, 201-206.
203. Duet, M., Mundler, O., Ajzenberg, C. A., Berolatti, B., Chedin, P., Duranteau, L., and Warnet, A. (1994) Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index. Eur. J. Nucl. Med. 21, 647-650.
204. 1]loctreotide. Eur. J. Nucl. Med. 21, 328-335.
205. Macke, H. R., and Behe, M. (1996) New octreotide derivatives labelled with technetium-99m. J. Nucl. Med. 37, 29P (abstract 107).
206. Behe, M., and Macke, H. R. (1995) New somatostatin analogues labelled with technetium-99m. Eur. J. Nucl. Med. 22, 791 (abstract 267).
207. Thakur, M. L., John, E., Li, J., Reddy, H. R., Halmos, G., and Schally, A. V. (1995) Tc-99m-RC-160: a somatostatin analog for imaging prostate cancer-comparison with I-125-RC-160, and In-111-octreotide. J. Nucl. Med. 36, 92P (abstract 374).
208. Thakur, M. L., Halmos, G., and Jan, J. (1994) Technetium-99m-RC-160: a somatostatin analog. J. Nucl. Med. 35, 259P (abstract 1063).
209. 1] substance P. J. Nucl. Med. 37, 108-117.
210. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl. Med. Biol. 23, 685-692.
211. Jurisson, S., Berning, D., Jia, W., and Ma, D.-S. (1993) Coordination compounds in nuclear medicine. Chem. Rev. 93, 1137-1156.